Daniel Millar leads Strategic Business Transformation in Quantitative Sciences at Janssen R&D. He is an advocate for utilizing quantitative innovation to advance patient-centric R&D while simultaneously delivering transformational efficiencies. Daniel is a founding leader and champion for multi-stakeholder engagement in the recently launched Innovative Medicines Initiative (IMI) public-private partnership for Integrated Research Platforms. Daniel obtained a MBA from the University of Chicago Booth School of Business and a BA in Mathematics from the University of Pennsylvania. He lives in Manhattan and enjoys traveling. His current “country number” is 115.

Abby Bronson is the Vice President of Patient Advocacy and External Innovation at Edgewise Therapeutics where she leads patient advocacy and external relationships within the Muscular Dystrophy community. Previously she was Senior Vice President of Research Strategy at PPMD, focusing on Duchenne Muscular Dystrophy. She has experience from a variety of areas, including NIH, Children's National Medical Center and MedImmune. She holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BA from the University of Vermont.

Amy Burd, Ph.D., is vice president of research strategy for The Leukemia & Lymphoma Society. Dr. Burd first began working with LLS in 2009 as senior director of LLS’s Therapy Acceleration Program. In her current role, Dr. Burd provides strategic planning and oversight for mission special initiatives. She also leads LLS’s Beat AML initiative, a significant multi-institution collaboration to change the paradigm of treatment and improve outcomes for patients with acute myeloid leukemia (AML).

Michelle Detry, PhD, is the Director of Adaptive Trial Execution and a Senior Statistical Scientist for Berry Consultants. Dr. Detry’s expertise is in the implementation of adaptive clinical trials, including platform trials. As part of her role in implementing Berry Consultant’s trial designs she is a member of numerous statistical analysis committees that conduct the interim analyses. In addition, she has expertise in clinical trial design, reporting for Data Monitoring Committees, and also serves on Data Monitoring Committees.

As Chief Data Officer of the Pancreatic Cancer Action Network (PanCAN), Sudheer is responsible for the health data generated from PanCAN’s scientific and clinical initiatives. Prior to joining PanCAN, Sudheer worked as a management consultant for over a decade where he led a variety of strategic initiatives, including market entry strategies, deals-related operational / commercial due diligence, and business launch strategies, all related to genomic medicine. Sudheer completed his doctorate and post-doctoral research at UCLA in the Department of Human Genetics where his research combined areas of network theory with genetics and global gene expression data to elucidate the genetic underpinnings of disease

AnnCatherine Downing received her Doctor of Pharmacy degree from Butler University in Indianapolis, Indiana. She has over 17 years of pharmaceutical industry experience across all phases of clinical development. She is currently a Sr. Clinical Research Advisor in Eli Lilly and Company's Design Hub responsible for clinical trial design across the neuroscience portfolio.

Ms. Fisher manages the development and implementation of CTTI projects. In collaboration with team leaders, she creates project plans and budgets, and manages the implementation of those plans. Ms. Fisher has over 7 years of project management experience in diverse research, clinical, and community settings. Prior to working at CTTI, her research and advocacy efforts largely focused on community-driven health education and research initiatives with low-income communities. She has served as a lead coordinator for research studies and community health education initiatives funded by the NIH, public health departments, pharmaceutical companies, and private foundations.

Scott Berry is President and a Senior Statistical Scientist at Berry Consultants, LLC. He earned his MS and PhD in statistics from Carnegie Mellon University and was an Assistant Professor at Texas A&M University before co-founding Berry Consultants in 2000. His primary interests are in Bayesian Analysis, Design of Innovative Trials, Platform Trials, Clinical Trial Simulation, and Hierarchical Modeling.

Lisa LaVange, PhD, is Professor and Chair of the Department of Biostatistics in the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill and former director of the department’s Collaborative Studies Coordinating Center (CSCC). From 2011 to 2017, Dr. LaVange was director of the Office of Biostatistics in the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Prior to her government and academic experience, she spent 16 years in non-profit research and 10 years in the pharmaceutical industry. Dr. LaVange is an elected fellow of the American Statistical Association (ASA) and was the 2018 ASA President.

Randall Bateman, MD is the Charles F. and Joanne Knight Distinguished Professor of Neurology. His research focuses on the pathophysiology and development of diagnostics and treatments of Alzheimer’s disease. His lab accomplishments include pioneering central nervous system Stable Isotope Labeling Kinetics (SILK) measurements in humans, furthering insights of human circadian patterns of amyloid-beta and soluble APP, and developing a blood test for brain amyloid plaques. Dr. Bateman directs the DIAN-TU, which launched the first prevention trial in families with early onset Alzheimer’s disease. The DIAN-TU trial is a global adaptive trial platform testing the most advanced therapeutics targeting Alzheimer’s disease.

Dr. Heather Dobbins holds a Staff Scientist position in the National Center for Biotechnology Information (NCBI) at the National Library of Medicine, where she serves as the Lead Results Analyst for ClinicalTrials.gov. In this capacity she oversees the submission, quality review process and investigator assistance services for the ClinicalTrials.gov Basic Results Database. Dr. Dobbins earned a B.S. in Physics, a B.S. in Biology and a Ph.D. in Neuroscience. She held a dual appointment as a Postdoctoral Research Associate and Howard Hughes Medical Institute Teaching and Learning Fellow in the Physics Education Research Group at the University of Maryland. She has been a member of the ClinicalTrials.gov Results Team since 2009.

Gregory Levin is the Associate Director for Statistical Science and Policy in the Office of Biostatistics in the FDA’s Center for Drug Evaluation and Research. He received a Ph.D. in biostatistics from the University of Washington in 2012. Greg has experience supporting drug review across a wide range of therapeutic areas and has represented CDER on several policy and guidance working groups, including efforts related to adaptive design, master protocols, benefit-risk, and the evaluation of effectiveness.

Sabrina Paganoni, MD, PhD is a physician investigator at the Healey Center for ALS at Mass General, Co-Director of the Neurological Research Institute at the Massachusetts General Hospital and Assistant Professor at Harvard Medical School. Dr Paganoni’s research focuses on clinical trials and therapy development for ALS. She has served as the Principal Investigator of many ALS clinical trials and has been using novel neuroimaging techniques, bio-fluid biomarkers and digital technology as measures of target engagement in these trials. Currently, she is the co-Principal Investigator of the HEALEY ALS Platform Trial. Her research has been funded by the NIH, several ALS Foundations and non-profits, and industry.

Dr. Price is the Deputy Director of the Office of Biostatistics. In her role at FDA, she promotes collaborative efforts to advance the use of complex innovative trial designs. An invited speaker at conferences world-wide, she has served as Chair of ASA’s Biopharmaceutical Section and on the Regional Committee of the Eastern North American Region of IBS. She is a Fellow of the ASA and the President-Elect of the ASA. With an MS in Biostatistics from UNC, and PhD from Emory, her research interests focus on clinical trial designs. She has co-authored papers in Statistics in Medicine, Clinical Trials, and Statistics in Biopharmaceutical Research.

Robin M. Weinick, PhD. brings 25 years of experience to her DIA role as Senior Vice President & Managing Director, Americas, and Global Program Officer.Robin joins DIA from RTI International, a large, nonprofit research institute dedicated to improving the human condition. She also has served as Associate Director for Health at the RAND Corporation, a premier U.S.-based think tank, and on the faculty of Harvard Medical School and Massachusetts General Hospital. She began her career in federal service with the U.S. Department of Health and Human Services. She holds a B.A. in Health and Society from the University of Rochester and a Ph.D. on Population Dynamics from Johns Hopkins University.

Shanna Allen is a Clinical Operations Regional Lead at the Global Coalition for Adaptive Research (GCAR) with over 15 years of experience in managing, leading, monitoring, and coordinating domestic and global Phase I-IV clinical trials across various therapeutic areas. As a Clinical Operations Regional Lead, she oversees the operational activities of master protocols, focusing on establishing processes for the appropriate handling of data. Prior to GCAR, Shanna served in management roles at pharmaceutical and biotechnology companies responsible for leading multidisciplinary teams in the execution of clinical trials from initiation through close-out.

Donald Berry is a professor in the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. He has held endowed faculty positions at Duke University and at M.D. Anderson. Dr. Berry has authored over 400 publications. He is listed by ScienceWatch.com as one of The World’s Most Influential Scientific Minds in Clinical Medicine in 2014. Through Berry Consultants he has designed innovative clinical trials in all therapeutic areas for industry and international consortia.

Marianne Kearney Chase is currently the Senior Director of Clinical Trial Operations for the Neurological Clinical Research Institute, and the Healey Center for ALS Research at MGH. She is an active member of the Clinical Trial Transformation Initiative (CTTI) and has over 25 years of experience in both investigator initiated NIH/ foundation funded, and industry sponsored research including protocol development, regulatory strategy and compliance, and project management. She also serves as an adjunct faculty member for the NINDS funded Clinical Trials Methodology Course and has developed and presented course on a variety of topics.

Dr. Lennie Derde is a clinician-researcher focussing on sepsis and severe infections in ICU and innovative trial design. She works at the UMC Utrecht as ICU consultant. She obtained a PhD on antibiotic resistance in the ICU in 2013 . She has been involved in REMAP-CAP since 2015, chairs the European RMC and is a member of the ITSC and various expertise groups. She recently obtained a Dutch grant (ZonMw) to investigate anakinra treatment of COVID-19 patients. Lennie chairs the Dutch ICU Taskforce for Infectious Threats.

Benjamin Hofner is Head of Data Science and Methods at the Paul-Ehrlich-Institut (PEI). In this role he is involved in the assessment of Clinical Trial Applications and Marketing Authorisation Applications, and provides Scientific Advice to stakeholders. He is member of the EMA Methodology Working Party ESEC and Adjunct Lecturer for Biostatistics at the medical school at FAU Erlangen-Nuremberg. Benjamin was involved in the IMI project EU-PEARL on patient centric research platforms as regulatory task lead and is member of the temporary drafting group (tDG) for the EMA reflection paper on platform trials.

Jane Perlmutter is long-term cancer survivor, involved in a wide-range of advocacy which is rooted in her own experiences, but also informed by her formal training and professional experience. She focuses on clinical trials--ensuring the patient voice is considered in selection of research questions, design of trial protocols, and encouraging innovation to increase the speed of developing new treatments. She is also involved in health research policy, including projects with CTTI, RUF and PCORI.

Dr. Janet Woodcock began her long and distinguished FDA career in 1986. In 1994, Dr. Woodcock was named Director of the CDER. In that position, she has led many of the FDA’s groundbreaking drug initiatives. In 2020 Dr. Woodcock was asked to lend her expertise to “Operation Warp Speed” the initiative to develop therapeutics in response to the pandemic. Dr. Woodcock was named Acting Commissioner of Food and Drugs on January 20, 2021-February 17, 2022. Dr. Woodcock is now the FDA's Principal Deputy Commissioner. In this role she works closely with the Commissioner of Food and Drugs to develop and implement key public health initiatives and helps oversee the agency’s day-to-day functions.

Janice Chang is the Chief Executive Officer at TransCelerate BioPharma Inc. She has been involved with the organization since its inception. In her current position, Janice works closely with the Board of Directors to shape the long-term strategic vision and priorities for the organization. Janice defines and guides TransCelerate’s overall external engagement strategy with global health authorities, governmental agencies, industry groups, and TransCelerate’s country network spanning across 30 countries. She has accountability overseeing TransCelerate’s corporate strategy and works closely with her team to drive operational delivery of TransCelerate’s mission and ongoing portfolio.

Phil was diagnosed with ALS in August of 2018 and immediately dedicated himself to making a difference in the fight against ALS. Phil is active with multiple ALS organizations and institutions (Team Gleason, I AM ALS, Augie’s Quest, ALS TDI, ALS Cure Project, UW Medicine, ALSA) with promoting ALS legislation and policies, increasing awareness and raising funds to find effective treatments and cures, and bringing the patient voice to biopharma companies on clinical trial design. He joined CTTI Steering Committee in 2021 as a Patient Representative. Phil is a graduate of the University of Washington where he was on the 1991 National Championship UW Football team.

Raj Malathker is currently the Sr. IT Manager (Business Technology Leader) within Pharma R&D IT at The Janssen Pharmaceutical Companies of Johnson & Johnson. Raj joined J&J in 2011 and his key responsibilities have been to define strategies and enable innovative technology solutions around Adaptive Clinical Trials, High Performance Computing for Pharmacometrics and Statistical Programming, in liaison with Pharma R&D groups such as Quantitative Sciences, Clinical Pharmacology & Pharmacometrics. Raj has a Computer Science & Engineering degree from Mysore University, India.

Lindsay McNair, MD, MPH, MSB is Principal Consultant at Equipoise Consulting. She was previously the Chief Medical Officer for WCG. In role she oversaw WCG IRB, and provided consultation to institutions and biopharma companies on a wide range of issues related to clinical protocol design, regulatory compliance, human subject protection, and ethical policy development. Prior to joining WCG, she was a consultant to pharmaceutical and biotechnology companies, providing medical oversight of all phases of clinical trials.

General Manager of Medicines and Biological Products at ANVISA, Brazil. Responsible for the management of drug and biological product registration submission evaluation teams, authorization to conduct clinical trials in Brazil, and certification of bioequivalence centers. I have been working at ANVISA, Brazil since 2003 mostly with bioequivalence / biowaiver studies and clinical trial evaluations. I'm a pharmacist with specialization in public health, I also holds a Master of Toxicology.

Susan Mills is the Senior Director, Clinical Operations within the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University in St. Louis, School of Medicine. She has a BS in both Chemistry and Biology from the University of California, Irvine, and while starting at the bench in cellular gastroenterology, she quickly found her passion in clinical research management, which proved to be a far more engaging and vocal subject matter. Over the past 20 years, she has both managed and directed global clinical trials over a broad therapeutic range of programs, including Phase II through IV trials contributing to approvals of NDAs, ANDAs, and BLAs.

Jay Park is the Founder and Scientific Lead of Core Clinical Sciences (CCS) with over 10 years of experience in complex innovative trial and quantitative research methods. He is also an Assistant Professor at McMaster University. Jay specializes in innovative trial designs (adaptive trial designs and master protocols), decision analytics, and evidence synthesis methods. At CCS, Jay helps clients explore and apply appropriate study designs and address difficult clinical development and reimbursement problems. Jay is the lead author of the book “Introduction to Adaptive Trial Designs and Master Protocols” with the Cambridge University Press. He regularly teaches a graduate-level course on complex innovative designs at McMaster University

Cecile Spiertz is a senior director at J&J, Head External Innovation, Clinical Trial Platforms and current project lead for the IMI Project EU-PEARL. She has a strong operational track record in successful delivery of global clinical development programs for Janssen Immunology R&D in her most recent positions as Global Operations Head and Strategy&Operations Lead for the Immunology clinical development organisation. She brings > 25 years of experience in phase 1, 2, 3 of drug development in various scientific and operational leadership roles, in different companies and is highly skilled in leading global cross-functional teams and innovation projects.

Tina Gislimberti is a Project Manager Director with considerable experience in oversight, management and coordination of multi-centre international clinical projects and project teams. Experience includes over 20 years within clinical project management. Tina's responsibilities have included customer project/program oversight, escalation point, primary key contact, budget and finance management, study document management, overall study conduct.

Dr. Sethi is VP Safety Operations at AbbVie. In 15 years in the pharmaceutical industry he has held roles in clinical development, regulatory affairs, medical affairs, and pharmacovigilance. Prior to industry Dr. Sethi worked at the Boston Consulting Group. His passions are transforming business process, technology, and organizations to realize higher performance and cross-company collaborations to advance industry capabilities. In 2019 Dr. Sethi was diagnosed with ALS, a progressive and fatal neurodegenerative disorder. While it has taken a significant toll he remains active in driving advocacy and research efforts for all patients and families stricken by this challenging disease. Dr. Sethi earned his BS, MBA, & MD from UCLA.

Dr. Mandrekar is a Professor of Biostatistics and Oncology as well the Group Statistician for the Alliance for Clinical Trials in Oncology and Section Head for Cancer Center Statistics at Mayo Clinic. Her primary areas are lung cancer and leukemia. She is the faculty statistician for the national adjuvant lung cancer trial, ALCHEMIST, which is part of the NCI precision medicine initiative. Her research interests include adaptive dose-finding trial designs for Phase I trials, designs for predictive biomarker validation, and general clinical trial methodology related to identification of alternative Phase II cancer clinical trial endpoints. Dr. Mandrekar has co-authored140+ original papers, several book chapters and editorials.

Phyllis Ferrell is the Global Head of External Engagement for Alzheimer’s disease and Neurodegeneration at Lilly. Ferrell has been an industry leader in Alzheimer's R&D for a decade and has been with Lilly for more than 25 years. Ferrell received a BA in economics from DePauw University and received an MBA in general management and a healthcare public management from Stanford. Phyllis was recognized as a Rising Star from the Healthcare Businesswomen’s Association and the Indianapolis Star Top 40 Under 40. Phyllis is a current member of the World Dementia Council and is on Executive Boards for the Indiana Alzheimer's Association, EdoN, the Indianapolis 500 Festival, and is co-chair of the Women Against Alzheimer's Leadership Council

Stephen Finger was diagnosed with ALS in 2013. A vocal advocate, Stephen actively participated in drafting the ALS Community Developed Guidance Document submitted to the FDA and served as a panelist at the ALS Guidance Workshop in 2018. He was a Patient Fellow during the 2017 ALS/MND International Research Symposium. He was awarded the 2014 Stephen Milne Adventurous Spirit Award by the ALS Therapy Development Institute. After earning degrees from Princeton and Duke, Dr. Finger was an economics professor at the Moore School of Business at the University of South Carolina. He now resides in Atlanta with his wife and two kids.

Tobias Mielke is a Scientific Director in Janssen's internal Quantitative Science consulting group, where he supports compound development teams with his expertise on adaptive designs. Prior to joining Janssen in 2018, Tobias worked at ICON Clinical Research, where he specialized on adaptive designs through numerous adaptive design consultancy projects. In his role at ICON, Tobias led the methodological development of ADDPLAN DF, a software for the design, simulation and analysis of adaptive dose-finding studies. Tobias applies this experience currently in the IMI project EU-PEARL as a co-lead for the development of a platform trial design & simulation software.

Dr. Lewis is Professor and former Chair in the Department of Emergency Medicine at Harbor-UCLA Medical Center and the Senior Medical Scientist at Berry Consultants, with expertise in the design and oversight of adaptive and platform clinical trials. He is a member of the National Academy of Medicine, and a prior member of the Board of Directors for the Society for Clinical Trials, and the Blood Products Advisory Committee of the FDA/CBER. He has served as a member of the Medicare Evidence Development & Coverage Advisory Committee for CMS and chaired numerous data and safety monitoring boards (DSMB). He has authored or coauthored over 270 original research publications, reviews, editorials, and chapters.

Geoffrey A. Kerchner, MD, PhD is a neurologist and neuroscientist and Global Development Leader at F. Hoffmann-La Roche, Ltd., in Basel, Switzerland. He graduated summa cum laude from Harvard University, completed MD and PhD degrees at Washington University School of Medicine, and completed a residency, postdoctoral fellowship, and behavioral neurology fellowship at the University of California, San Francisco. He was on the faculty of Stanford School of Medicine before joining Genentech/Roche in 2015, where he led early-stage clinical development teams in Alzheimer's disease and ALS. He moved to Basel in 2018 to lead the late-stage clinical development team for gantenerumab in Alzheimer's disease.

Nicholas C. Richardson DO, MPH, is a pediatric oncologist in the Division of Hematologic Malignancies 2 within the Office of Oncologic Diseases, at the Food and Drug Administration (FDA). Prior to joining the FDA, he completed his pediatric residency and chief residency at A.I. duPont Hospital for Children/Thomas Jefferson University and fellowship in pediatric hematology and oncology at Vanderbilt University Medical Center. Dr. Richardson’s is currently a clinical team leader for lymphoma drug development and his clinical interest include Hodgkin and non-Hodgkin lymphoma, pediatric drug development in oncology, patient advocate engagement, and innovative trials designs such as master protocols.

I am an Associate professor in the Department of Investigational Cancer Therapeutics, Associate Professor in Division of Pediatrics, the Center Clinical Medical Director of the Clinical Center for Targeted Therapy ( Phase 1 Clinical Trials Program) and Executive Director of Cancer Medicine Research, MD Anderson Cancer Network. I serve as the Principal Investigator in over 50 Phase I/II trials. My research interests are drug development in rare cancer. I have led several first-in-human and practice changing novel basket trials leading to FDA approval in rare diseases in BRAF V600E and RET inhibitor space. Published several prestigious journals eg. NEJM, JCO, Cancer Discovery, Lancet Oncology & JAMA Oncology

Gene Vinson has over 15 years’ experience in a clinical research organization (CRO) and is currently the Senior Director of Global Data Technologies in Biometrics at Syneos Health. Gene has lead the implementation of multiple EDC Systems and is an expert in the implementation of Electronic Data Capture. Gene is currently working with eSource systems, wearables and the integration of Electronic Health Record data into EDC systems and the integration of clinical data into the Syneos Health Data Lake, development of reporting and analytics data for analysis and trial management.

Kert Viele is the Director of Research at Berry Consultants. He is a leader in clinical trial implementation of Bayesian hierarchical modeling, with expertise in platform and basket trials as well as clinical trials incorporating the use of historical information. He has authored or co-authored over 50 peer reviewed papers and developed over 100 custom Bayesian adaptive clinical trials for clients in industry, government, and academia, A former editor of the journal Bayesian Analysis, Dr. Viele is also an author of FACTS (Fixed and Adaptive Clinical Trial Simulator), clinical trial simulation software currently licensed to multiple industry, academic, and regulatory organizations.